DRUG vs NABL

Comparison between Bright Minds Biosciences Inc (DRUG, Company) and N-able Inc (NABL, Company).

DRUG is from the Healthcare sector, while NABL is from the Technology sector.

5-Year PerformanceDRUG has outperformed NABL, delivering a return of +21.5% compared to -28.6%

DRUG vs NABL - Performance Comparison

Log

Key Characteristics

Financial metrics and valuation ratios

Metric	DRUG(COMPANY)	NABL(COMPANY)
Market Cap	$582M	$576M
Max Drawdown	97.68%	80.94%
Sharpe Ratio	1.38	-1.66
5Y Beta	-0.80	0.92
Industry	Biotechnology	Information Technology Services
P/E Ratio	-24.65	-54.66
Forward P/E	N/A	7.26
PEG Ratio	-0.07	N/A
5Y EPS CAGR	8.42%	N/A
Debt to Equity	0.03%	49.21%
Free Cash Flow Yield	-2.50%	12.92%

Market Cap

Winner

DRUG

$582M

NABL

$576M

Max Drawdown

DRUG

97.68%

Winner

NABL

80.94%

Sharpe Ratio

Winner

DRUG

1.38

NABL

-1.66

5Y Beta

Winner

DRUG

-0.80

NABL

0.92

Industry

DRUG

Biotechnology

NABL

Information Technology Services

P/E Ratio

DRUG

-24.65

Winner

NABL

-54.66

Forward P/E

DRUG

N/A

NABL

7.26

PEG Ratio

DRUG

-0.07

NABL

N/A

5Y EPS CAGR

DRUG

8.42%

NABL

N/A

Debt to Equity

Winner

DRUG

0.03%

NABL

49.21%

Free Cash Flow Yield

DRUG

-2.50%

Winner

NABL

12.92%

DRUG vs NABL - Historical Returns

Returns include dividend reinvestment.

Period	DRUG	NABL
1 month	-19.12%	-14.76%
3 months	-13.16%	-39.29%
6 months	-23.10%	-60.10%
1 year	+115.18%	-61.22%
5 years(CAGR)	+21.53%	-28.58%
Max(CAGR)	+16.70%	-28.58%

DRUG

-19.12%

Winner

NABL

-14.76%

Winner

DRUG

-13.16%

NABL

-39.29%

Winner

DRUG

-23.10%

NABL

-60.10%

Winner

DRUG

+115.18%

NABL

-61.22%

5Y(CAGR)

Winner

DRUG

+21.53%

NABL

-28.58%

Max(CAGR)

Winner

DRUG

+16.70%

NABL

-28.58%

DRUG vs NABL - Annual Returns (2021 - 2026)

Returns include dividend reinvestment.

Year	DRUG	NABL
2026	-27.32%	-58.08%
2025	+89.83%	-19.14%
2024	+1859.10%	-29.30%
2023	-63.33%	+28.52%
2022	-78.04%	-10.61%
2021	-41.30%	-30.63%

DRUG vs NABL Drawdown Comparison

The maximum drawdown for DRUG was -97.68%, occurring on Jul 11, 2024. Recovery took 740 trading sessions.

The maximum drawdown for NABL was -80.94%, occurring on Jun 17, 2026. This drawdown has not yet recovered.

The current DRUG drawdown is -36.80%. The current NABL drawdown is -80.88%.

Rank	DRUG	NABL
#1	-97.68% Nov 8, 2021 - Oct 18, 2024	-80.94% Jul 19, 2021 - Jun 17, 2026
#2	-58.28% Nov 6, 2024 - Sep 29, 2025	N/A
#3	-38.35% Jan 7, 2026 - Jun 15, 2026	N/A
#4	-27.84% Mar 22, 2021 - Aug 24, 2021	N/A
#5	-26.13% Oct 21, 2025 - Nov 28, 2025	N/A
#6	-19.30% Dec 16, 2025 - Jan 7, 2026	N/A
#7	-16.21% Sep 30, 2025 - Oct 9, 2025	N/A
#8	-14.42% Oct 11, 2021 - Nov 3, 2021	N/A
#9	-9.05% Oct 24, 2024 - Nov 4, 2024	N/A
#10	-7.65% Oct 14, 2025 - Oct 21, 2025	N/A
#11	-5.42% Dec 11, 2025 - Dec 16, 2025	N/A
#12	-4.62% Sep 24, 2021 - Sep 29, 2021	N/A
#13	-4.59% Dec 8, 2025 - Dec 10, 2025	N/A
#14	-4.38% Aug 24, 2021 - Sep 1, 2021	N/A
#15	-3.81% Sep 1, 2021 - Sep 17, 2021	N/A